22 Nov 2017
Posted by Andrew Kantor
Eli Lilly is considering whether to trademark the phrase “A chance to live longer.” Bristol-Myers Squibb wants to register it, but Lilly used it first.
That’s almost 120,000 Georgians who have bought healthcare coverage through the Obamacare exchange. (The U.S. total so far is about 2.3 million.) Even with the shorter sign-up period, the state is expected to meet if not exceed its 2017 total.
Researchers have looked into possible health benefits of cinnamon for a while. And while there’s no evidence it helps with glucose levels, it does seem to help burn fat better. And a new study gets a little deeper into why that happens.
Downer: There are two types of cinnamon (Ceylon and cassia), and while the cassia is what you find in your supermarket, it’s the Ceylon version that has the medicinal properties.
If you’re an opioid, that depends. According to a Columbia University study, if you were born between 1947 and 1964, you have “a significantly higher risk of death from overdose of both prescription opioids and heroin.”
BUT … if you were born between ’79 and ’92, you have a higher risk of overdosing specifically from heroin.
Why? Because Boomers had a “high rate of illicit drug use,” while Millennials just like new experiences.
The FDA approved GSK’s Juluca, a two-drug combo to treat HIV. Until now, the only approved treatments were three or more drug regimens*.
The company’s CEO called the drug “critical,” but not for treating HIV — for ‘filling the revenue gap’ left by declining sales of Advair.
Remember rofecoxib, aka Vioxx? It was supposed to treat pain but caused heart attacks and strokes instead.
Now a small pharma company wants to bring it back — but this time as a hemophilia treatment. Unlike other pain killers, Vioxx doesn’t raise the risk of internal bleeding — and it’s not an opioid, either.